These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
599 related items for PubMed ID: 10191222
1. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222 [Abstract] [Full Text] [Related]
7. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180 [Abstract] [Full Text] [Related]
8. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM, Waugh J, Noble S. Drugs; 2003 Oct; 63(22):2501-20. PubMed ID: 14609360 [Abstract] [Full Text] [Related]
9. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria. Strateva T, Petrova G, Mitov I. J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744 [Abstract] [Full Text] [Related]
18. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. Treerat P, Widmer F, Middleton PG, Iredell J, George AM. FEMS Microbiol Lett; 2008 Aug 17; 285(1):40-50. PubMed ID: 18513356 [Abstract] [Full Text] [Related]